BACKGROUND: Transplantation of the pancreas has become the treatment of choice for selected patients with type 1 diabetes mellitus. With the current shortage of cadaver donors and the increasing number of diabetic patients on the transplant waiting list, there is a critical need to optimally use all available pancreas grafts for transplantation. We have therefore explored the use of traditionally "less-than-ideal" pancreas donors, including pediatric (4-10 years), older (>or=45 years), obese (weight >or=200 lb), and non-heart-beating donors and donors with an elevated amylase (75% greater than normal values). METHODS: A total of 620 primary simultaneous pancreas-kidney transplantations were performed at our center. We analyzed the ratio of livers to pancreata transplanted at our center and compared this to the United Network for Organ Sharing database. Using univariate and multivariate analyses, we then assessed the impact of these less-than-ideal donors on patient survival, graft survival, and postsurgical complications after simultaneous pancreas-kidney transplantation. RESULTS: A substantial nationwide underutilization of pancreata from donor procurements is demonstrated in the United Network for Organ Sharing database. By using these less-than-ideal donors, the ratio of liver to pancreata procured can be reduced to 1.25:1. Graft survival was not significantly different in patients receiving transplants from obese, non-heart-beating, pediatric, or hyperamylasemic donors compared with grafts from ideal donors. However, grafts from donors 45 years of age or older had significantly lower 1- and 5-year graft survival rates (76% and 65% vs. 90% and 80%, P=0.006). CONCLUSIONS: This study demonstrates that utilization of pancreas grafts from selected, less-than-ideal donors results in good overall outcomes and could potentially expand the organ donor pool.
BACKGROUND: Transplantation of the pancreas has become the treatment of choice for selected patients with type 1 diabetes mellitus. With the current shortage of cadaver donors and the increasing number of diabeticpatients on the transplant waiting list, there is a critical need to optimally use all available pancreas grafts for transplantation. We have therefore explored the use of traditionally "less-than-ideal" pancreas donors, including pediatric (4-10 years), older (>or=45 years), obese (weight >or=200 lb), and non-heart-beating donors and donors with an elevated amylase (75% greater than normal values). METHODS: A total of 620 primary simultaneous pancreas-kidney transplantations were performed at our center. We analyzed the ratio of livers to pancreata transplanted at our center and compared this to the United Network for Organ Sharing database. Using univariate and multivariate analyses, we then assessed the impact of these less-than-ideal donors on patient survival, graft survival, and postsurgical complications after simultaneous pancreas-kidney transplantation. RESULTS: A substantial nationwide underutilization of pancreata from donor procurements is demonstrated in the United Network for Organ Sharing database. By using these less-than-ideal donors, the ratio of liver to pancreata procured can be reduced to 1.25:1. Graft survival was not significantly different in patients receiving transplants from obese, non-heart-beating, pediatric, or hyperamylasemic donors compared with grafts from ideal donors. However, grafts from donors 45 years of age or older had significantly lower 1- and 5-year graft survival rates (76% and 65% vs. 90% and 80%, P=0.006). CONCLUSIONS: This study demonstrates that utilization of pancreas grafts from selected, less-than-ideal donors results in good overall outcomes and could potentially expand the organ donor pool.
Authors: Ngoc L Thai; Kareem Abu-Elmagd; Akhar Khan; Geoffrey Bond; Amit Basu; Kusum Tom; George Mazariegos; Rakesh Sindhi; Jorge Reyes; Henkie P Tan; Amadeo Marcos; Thomas E Starzl; Ron Shapiro Journal: Clin Transpl Date: 2004
Authors: J P Lindahl; A Hartmann; R Horneland; H Holdaas; A V Reisæter; K Midtvedt; T Leivestad; O Oyen; T Jenssen Journal: Diabetologia Date: 2013-04-03 Impact factor: 10.122
Authors: Luis A Fernandez; Antonio Di Carlo; Jon S Odorico; Glen E Leverson; Brian D Shames; Yolanda T Becker; L Thomas Chin; John D Pirsch; Stuart J Knechtle; David P Foley; Hans W Sollinger; Anthony M D'Alessandro Journal: Ann Surg Date: 2005-11 Impact factor: 12.969
Authors: Peter Thomas Fellmer; Andreas Pascher; Andreas Kahl; Frank Ulrich; Katharina Lanzenberger; Konstanze Schnell; Sven Jonas; Stefan G Tullius; Peter Neuhaus; Johann Pratschke Journal: Langenbecks Arch Surg Date: 2010-01 Impact factor: 3.445
Authors: A Miki; C Ricordi; S Messinger; T Yamamoto; A Mita; S Barker; R Haetter; A Khan; R Alejandro; H Ichii Journal: Cell Transplant Date: 2009 Impact factor: 4.064
Authors: Karl Philipp Drewitz; Martin Loss; Julika Loss; Christian Joachim Apfelbacher Journal: BMC Health Serv Res Date: 2014-11-25 Impact factor: 2.655
Authors: Andrea Proneth; Andreas A Schnitzbauer; Florian Zeman; Johanna R Foerster; Ines Holub; Helmut Arbogast; Wolf O Bechstein; Thomas Becker; Carsten Dietz; Markus Guba; Michael Heise; Sven Jonas; Stephan Kersting; Jürgen Klempnauer; Steffen Manekeller; Volker Müller; Silvio Nadalin; Björn Nashan; Andreas Pascher; Falk Rauchfuss; Michael A Ströhlein; Peter Schemmer; Peter Schenker; Stefan Thorban; Thomas Vogel; Axel O Rahmel; Richard Viebahn; Bernhard Banas; Edward K Geissler; Hans J Schlitt; Stefan A Farkas Journal: Transplant Res Date: 2013-07-01